210 related articles for article (PubMed ID: 37852928)
61. Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.
Yin X; Liu Y; Sun J; Tong H; Meng H; You L
Ther Adv Chronic Dis; 2023; 14():20406223231213251. PubMed ID: 38028949
[TBL] [Abstract][Full Text] [Related]
62. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
63. Talquetamab in multiple myeloma.
Liu L; Krishnan A
Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
[TBL] [Abstract][Full Text] [Related]
64. [Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy].
Le Grand S; Karlin L
Bull Cancer; 2023 Sep; 110(9):871-872. PubMed ID: 37296008
[No Abstract] [Full Text] [Related]
65. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review.
Khanam R; Ashruf OS; Waqar SHB; Shah Z; Batool S; Mehreen R; Pachika P; Roksana Z; Rehman MEU; Anwer F
Antibodies (Basel); 2023 May; 12(2):. PubMed ID: 37366654
[TBL] [Abstract][Full Text] [Related]
66. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
67. CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma.
Chen X; Wong OK; Reiman L; Sherbenou DW; Post L
Mol Cancer Ther; 2024 Feb; 23(2):127-138. PubMed ID: 37816503
[TBL] [Abstract][Full Text] [Related]
68. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
[TBL] [Abstract][Full Text] [Related]
69. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
70. Elranatamab: First Approval.
Dhillon S
Drugs; 2023 Nov; 83(17):1621-1627. PubMed ID: 37924427
[TBL] [Abstract][Full Text] [Related]
71. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
Morè S; Corvatta L; Manieri VM; Morsia E; Poloni A; Offidani M
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004493
[TBL] [Abstract][Full Text] [Related]
72. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
73. The evolving therapy of DLBCL: Bispecific antibodies.
Hutchings M
Hematol Oncol; 2023 Jun; 41(S1):107-111. PubMed ID: 37294965
[TBL] [Abstract][Full Text] [Related]
74. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Frerichs KA; Verkleij CPM; Mateos MV; Martin TG; Rodriguez C; Nooka A; Banerjee A; Chastain K; Perales-Puchalt A; Stephenson T; Uhlar C; Kobos R; van der Holt B; Kruyswijk S; Kuipers MT; Groen K; Vishwamitra D; Skerget S; Cortes-Selva D; Doyle M; Zaaijer HL; Zweegman S; Verona RI; van de Donk NWCJ
Blood Adv; 2024 Jan; 8(1):194-206. PubMed ID: 38052042
[TBL] [Abstract][Full Text] [Related]
75. Novel treatment strategies for hematological malignancies in the immunotherapy era.
Imai Y
Int J Hematol; 2024 Jun; ():. PubMed ID: 38861242
[TBL] [Abstract][Full Text] [Related]
76. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Le Ray E; Jagannath S; Palumbo A
Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
[TBL] [Abstract][Full Text] [Related]
77. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
[TBL] [Abstract][Full Text] [Related]
78. Antibody therapies for multiple myeloma.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
Expert Opin Biol Ther; 2020 Mar; 20(3):295-303. PubMed ID: 31944131
[No Abstract] [Full Text] [Related]
79. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
80. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]